{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T17:42:25Z","timestamp":1774806145253,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Juvenile idiopathic arthritis (JIA) is common and difficult to treat. Cannabidiol (CBD) is now widely available, but no studies to date have investigated the use of CBD for JIA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a chart review to identify patients with JIA at a Midwestern medical institution between 2017 and 2019. We surveyed primary caregivers of JIA patients using an anonymous, online survey with questions on caregiver knowledge and attitudes towards CBD. We compared respondents with no interest in CBD use vs. those contemplating or currently using CBD using descriptive statistics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 900 reviewed charts, 422 met inclusion criteria. Of these, 236 consented to be sent a survey link, and <jats:italic>n<\/jats:italic>=136 (58%) completed surveys. Overall, 34.5% (<jats:italic>n<\/jats:italic>=47) of respondents reported no interest in using a CBD product for their child\u2019s JIA, while 54% (<jats:italic>n<\/jats:italic>=79) reported contemplating using CBD and 7% (<jats:italic>n<\/jats:italic>=10) reported currently giving their child CBD. Only 2% of respondents contemplating or actively using a CBD product learned about CBD from their child\u2019s rheumatologist, compared with television (70%) or a friend (50%). Most respondents had not talked to their child\u2019s rheumatologist about using CBD. Of those currently using CBD, most used oral or topical products, and only 10% of respondents (<jats:italic>n<\/jats:italic>=1) knew what dose they were giving their child.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results show infrequent use but a large interest in CBD among caregivers of children with JIA. Given CBD\u2019s unknown safety profile in children with JIA, this study highlights a need for better studies and education around CBD for pediatric rheumatologists.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-021-00656-5","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T15:03:52Z","timestamp":1639407832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"19","author":[{"given":"Christopher J","family":"Failing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin F.","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Riebschleger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"issue":"7","key":"656_CR1","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/rheumatology\/ken039","volume":"47","author":"J Thornton","year":"2008","unstructured":"Thornton J, Lunt M, Ashcroft D, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology. 2008;47(7):985\u201390.","journal-title":"Rheumatology"},{"issue":"6","key":"656_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/14740338.2020.1763300","volume":"19","author":"I Maccora","year":"2020","unstructured":"Maccora I, dell\u2019Anna MP, Vannacci A, Simonini G. Safety evaluations of adalimumab for childhood chronic rheumatic diseases. Expert opinion on drug safety. 2020;19(6):661\u201371.","journal-title":"Expert opinion on drug safety"},{"issue":"1","key":"656_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-017-0025-2","volume":"2","author":"ER Weitzman","year":"2018","unstructured":"Weitzman ER, Wisk LE, Salimian PK, Magane KM, Dedeoglu F, Hersh AO, et al. Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis. Journal of patient-reported outcomes. 2018;2(1):1\u201311.","journal-title":"Journal of patient-reported outcomes"},{"issue":"5","key":"656_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3899\/jrheum.171087","volume":"45","author":"LA Favier","year":"2018","unstructured":"Favier LA, Taylor J, Rich KL, Jones KB, Vora SS, Harris JG, et al. Barriers to adherence in juvenile idiopathic arthritis: a multicenter collaborative experience and preliminary results. The Journal of rheumatology. 2018;45(5):690\u20136.","journal-title":"The Journal of rheumatology"},{"key":"656_CR5","doi-asserted-by":"crossref","unstructured":"Rouster-Stevens K, Nageswaran S, Arcury TA, Kemper KJ. How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies? BMC complementary and alternative medicine. 2008;8(1):1\u20139.","DOI":"10.1186\/1472-6882-8-25"},{"issue":"1","key":"656_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/art.10931","volume":"49","author":"LE Hagen","year":"2003","unstructured":"Hagen LE, Schneider R, Stephens D, Modrusan D, Feldman BM. Use of complementary and alternative medicine by pediatric rheumatology patients. Arthritis Care & Research: Official Journal of the American College of Rheumatology. 2003;49(1):3\u20136.","journal-title":"Arthritis Care & Research: Official Journal of the American College of Rheumatology"},{"issue":"10","key":"656_CR7","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3899\/jrheum.081295","volume":"36","author":"K Toupin-April","year":"2009","unstructured":"Toupin-April K, Feldman DE, Zunzunegui MV, Descarreaux M, Malleson P, Duffy CM. Is complementary and alternative healthcare use associated with better outcomes in children with juvenile idiopathic arthritis? The Journal of rheumatology. 2009;36(10):2302\u20137.","journal-title":"The Journal of rheumatology"},{"issue":"4","key":"656_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ctim.2009.03.003","volume":"17","author":"KT April","year":"2009","unstructured":"April KT, Feldman DE, Zunzunegui MV, Descarreaux M, Malleson P, Duffy CM. Longitudinal analysis of complementary and alternative health care use in children with juvenile idiopathic arthritis. Complementary therapies in medicine. 2009;17(4):208\u201315.","journal-title":"Complementary therapies in medicine"},{"issue":"4","key":"656_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/art.20536","volume":"51","author":"DE Feldman","year":"2004","unstructured":"Feldman DE, Duffy C, De Civita M, Malleson P, Philibert L, Gibbon M, et al. Factors associated with the use of complementary and alternative medicine in juvenile idiopathic arthritis. Arthritis Care & Research. 2004;51(4):527\u201332.","journal-title":"Arthritis Care & Research"},{"issue":"2","key":"656_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jadohealth.2012.01.003","volume":"51","author":"EM Seburg","year":"2012","unstructured":"Seburg EM, Horvath KJ, Garwick AW, McMorris BJ, Vehe RK, Scal P. Complementary and alternative medicine use among youth with juvenile arthritis: are youth using CAM, but not talking about it? Journal of adolescent health. 2012;51(2):200\u20132.","journal-title":"Journal of adolescent health"},{"key":"656_CR11","doi-asserted-by":"crossref","unstructured":"Corroon J, MacKay D, Dolphin W. Labeling of Cannabidiol Products: A Public Health Perspective. Cannabis and Cannabinoid Research. 2020.","DOI":"10.1089\/can.2019.0101"},{"issue":"1","key":"656_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/can.2018.0006","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152\u201361.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"5","key":"656_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jpain.2020.12.001","volume":"22","author":"KF Boehnke","year":"2021","unstructured":"Boehnke KF, Gagnier JJ, Matallana L, Williams DA. Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey. J Pain. 2021;22(5):556\u201366.","journal-title":"J Pain"},{"issue":"6","key":"656_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejp.818","volume":"20","author":"DC Hammell","year":"2016","unstructured":"Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20(6):936\u201348.","journal-title":"Eur J Pain"},{"issue":"17","key":"656_CR15","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1073\/pnas.160105897","volume":"97","author":"AM Malfait","year":"2000","unstructured":"Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"656_CR16","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011\u201320.","journal-title":"N Engl J Med"},{"issue":"10125","key":"656_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085\u201396.","journal-title":"Lancet"},{"key":"656_CR18","doi-asserted-by":"crossref","unstructured":"Hurd YL. Leading the Next CBD Wave-Safety and Efficacy. JAMA Psychiatry. 2020.","DOI":"10.1001\/jamapsychiatry.2019.4157"},{"issue":"8","key":"656_CR19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037\u201343.","journal-title":"Neurochem Res"},{"issue":"20","key":"656_CR20","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790\u2013805.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"656_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/jcm8070989","volume":"8","author":"JD Brown","year":"2019","unstructured":"Brown JD, Winterstein AG. Potential adverse drug events and drug\u2013drug interactions with medical and consumer cannabidiol (CBD) use. Journal of clinical medicine. 2019;8(7):989.","journal-title":"Journal of clinical medicine"},{"issue":"1","key":"656_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MOP.0000000000000861","volume":"32","author":"L Singer","year":"2020","unstructured":"Singer L, Tokish H, Park F, Campisi C, Milanaik RL. The cannabidiol conundrum: potential benefits and risks of cannabidiol products for children. Current opinion in pediatrics. 2020;32(1):198\u2013205.","journal-title":"Current opinion in pediatrics"},{"issue":"1","key":"656_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000489287","volume":"1","author":"A Hazekamp","year":"2018","unstructured":"Hazekamp A. The trouble with CBD oil. Medical cannabis and cannabinoids. 2018;1(1):65\u201372.","journal-title":"Medical cannabis and cannabinoids"},{"issue":"17","key":"656_CR24","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2017.11909","volume":"318","author":"MO Bonn-Miller","year":"2017","unstructured":"Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708\u20139.","journal-title":"JAMA"},{"issue":"1","key":"656_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6882-14-124","volume":"14","author":"P Nousiainen","year":"2014","unstructured":"Nousiainen P, Merras-Salmio L, Aalto K, Kolho K-L. Complementary and alternative medicine use in adolescents with inflammatory bowel disease and juvenile idiopathic arthritis. BMC complementary and alternative medicine. 2014;14(1):1\u20137.","journal-title":"BMC complementary and alternative medicine"},{"issue":"1","key":"656_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11606-019-05335-6","volume":"35","author":"JH Ishida","year":"2020","unstructured":"Ishida JH, Zhang AJ, Steigerwald S, Cohen BE, Vali M, Keyhani S. Sources of Information and Beliefs About the Health Effects of Marijuana. J Gen Intern Med. 2020;35(1):153\u20139.","journal-title":"J Gen Intern Med"},{"issue":"7","key":"656_CR27","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1080\/10826084.2020.1729201","volume":"55","author":"M Wheeler","year":"2020","unstructured":"Wheeler M, Merten JW, Gordon BT, Hamadi H. CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults. Subst Use Misuse. 2020;55(7):1138\u201345.","journal-title":"Subst Use Misuse"},{"key":"656_CR28","doi-asserted-by":"crossref","unstructured":"Nitecka-Buchta A, Nowak-Wachol A, Wachol K, Walczynska-Dragon K, Olczyk P, Batoryna O, et al. Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. J Clin Med. 2019;8(11).","DOI":"10.3390\/jcm8111886"},{"key":"656_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/138920102001190306101821","volume":"20","author":"HX Dixon","year":"2019","unstructured":"Dixon HX, Benjamin DC, Meng T, Yujiang F. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Current Pharmaceutical Biotechnology. 2019;20:1\u201313.","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"1","key":"656_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121\u201330.","journal-title":"J Psychopharmacol"},{"key":"656_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimaraes FS, et al. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Front Pharmacol. 2017;8:259.","journal-title":"Front Pharmacol"},{"key":"656_CR32","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","volume":"10","author":"N Masataka","year":"2019","unstructured":"Masataka N. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Front Psychol. 2019;10:2466.","journal-title":"Front Psychol"},{"issue":"6","key":"656_CR33","doi-asserted-by":"publisher","first-page":"e028197","DOI":"10.1136\/bmjopen-2018-028197","volume":"9","author":"O Hendricks","year":"2019","unstructured":"Hendricks O, Andersen TE, Christiansen AA, Primdahl J, Hauge EM, Ellingsen T, et al. Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study. BMJ Open. 2019;9(6):e028197.","journal-title":"BMJ Open"},{"issue":"14","key":"656_CR34","doi-asserted-by":"publisher","first-page":"e1204-e11","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204-e11.","journal-title":"Neurology"},{"key":"656_CR35","unstructured":"Foundation A. Arthritis Foundation CBD Guidance for Adults 2019 ["}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00656-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00656-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00656-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T15:10:49Z","timestamp":1639408249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00656-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00656-5","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"7 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures and protocols were approved by the Institutional Review Board (IRB) at the University of Michigan (HUM00169198).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}